NR1H4 and metabolic dysfunction-associated steatohepatitis: The latest study revealed that the FXR agonist HPG1860 displayed promising antifibrotic effects in clinical treatment for NASH, with reduced pruritus, and the notable finding was that there was no significant elevation of LDL-C within 16 weeks [224].